Literature DB >> 18379872

Endothelin-1 reduces p-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier.

Alexandra Hembury1, Aloïse Mabondzo.   

Abstract

AIMS: It is a huge challenge to understand the blood-brain barrier (BBB), which is a key element in neuroinflammation associated with many brain diseases. The BBB also regulates the passage of xenobiotics into the central nervous system (CNS), and therefore influences drug efficacy. This may be due to the presence of ATP binding cassette transporters such as P-glycoprotein (Pgp) on the BBB, which are efflux pumps known to transport many drugs. The peptide endothelin 1 (ET-1) is involved in different kinds of CNS diseases and neuroinflammation, and is known to modulate Pgp transport activity. Although there are data from animal models, data from human models are scarce. We evaluated Pgp expression and transport activity in adult human brain microvascular endothelial cells (HBMECs) when exposing an adult human in vitro BBB model to ET-1.
METHODS: Adult HBMECs were cocultured with human adult glial cells on a Transwells to mimic blood and CNS compartments. These human in vitro BBBs were exposed for 24 h to 100 nM and 10 nM ET-1. Pgp expression was assessed by flow cytometry and its transport activity by measuring radiolabelled digoxin passage.
RESULTS: After exposure to ET-1, flow cytometry showed no shift of fluorescence intensity for a Pgp specific antibody. The passage of digoxin increased with a significant decrease of Q ratio for 10 nM ET-1.
CONCLUSION: Our results show that ET-1 has no effect on Pgp expression of adult HBMECs, but does modulate Pgp transport activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379872     DOI: 10.1007/s10571-008-9277-y

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  54 in total

Review 1.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

2.  A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation.

Authors:  Isabelle Megard; Alexia Garrigues; Stéphane Orlowski; Sylvie Jorajuria; Pascal Clayette; Eric Ezan; Aloïse Mabondzo
Journal:  Brain Res       Date:  2002-02-15       Impact factor: 3.252

Review 3.  Endothelin, its diverse biological activities and mechanisms of action.

Authors:  Y Takuwa; M Yanagisawa; N Takuwa; T Masaki
Journal:  Prog Growth Factor Res       Date:  1989

4.  Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis.

Authors:  L Speciale; M Sarasella; S Ruzzante; D Caputo; R Mancuso; M G Calvo; F R Guerini; P Ferrante
Journal:  J Neurovirol       Date:  2000-05       Impact factor: 2.643

5.  Endothelin evokes efflux of glutamate in cultures of rat astrocytes.

Authors:  Y Sasaki; M Takimoto; K Oda; T Früh; M Takai; T Okada; S Hori
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

Review 6.  Therapeutic effects of endothelin receptor antagonists in stroke.

Authors:  F C Barone; R N Willette; T L Yue; G Feurestein
Journal:  Neurol Res       Date:  1995-08       Impact factor: 2.448

7.  Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Authors:  Edward T Morgan; Kerry B Goralski; Micheline Piquette-Miller; Kenneth W Renton; Graham R Robertson; Madhusudana R Chaluvadi; Kellie A Charles; Stephen J Clarke; Marina Kacevska; Christopher Liddle; Terrilyn A Richardson; Rohini Sharma; Christopher J Sinal
Journal:  Drug Metab Dispos       Date:  2008-02       Impact factor: 3.922

8.  Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.

Authors:  Kerry B Goralski; Georgy Hartmann; Micheline Piquette-Miller; Kenneth W Renton
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Thrombin is a regulator of astrocytic endothelin-1.

Authors:  H Ehrenreich; T Costa; K A Clouse; R M Pluta; Y Ogino; J E Coligan; P R Burd
Journal:  Brain Res       Date:  1993-01-15       Impact factor: 3.252

10.  Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT.

Authors:  David Théron; Sylvie Barraud de Lagerie; Sylviane Tardivel; Hélène Pélerin; Philippe Demeuse; Claire Mercier; Aloïse Mabondzo; Robert Farinotti; Bernard Lacour; Françoise Roux; François Gimenez
Journal:  Biochem Pharmacol       Date:  2003-08-15       Impact factor: 5.858

View more
  5 in total

1.  Minimally invasive procedures reduce perihematomal endothelin-1 levels and the permeability of the BBB in a rabbit model of intracerebral hematoma.

Authors:  Likun Wang; Guofeng Wu; Fei Sheng; Fan Wang; Anrong Feng
Journal:  Neurol Sci       Date:  2012-02-05       Impact factor: 3.307

2.  Drug transport into the central nervous system: using newer findings about the blood-brain barriers.

Authors:  William A Banks
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

3.  Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways.

Authors:  Mohamad A Salkeni; Jessica L Lynch; Tulin Otamis-Price; William A Banks
Journal:  J Neuroimmune Pharmacol       Date:  2008-11-28       Impact factor: 4.147

4.  The multidrug resistance 1 gene Abcb1 in brain and placenta: comparative analysis in human and guinea pig.

Authors:  Jane J Pappas; Sophie Petropoulos; Matthew Suderman; Majid Iqbal; Vasilis Moisiadis; Gustavo Turecki; Stephen G Matthews; Moshe Szyf
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

5.  Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity.

Authors:  Rania Harati; Anne-Sophie Villégier; William A Banks; Aloise Mabondzo
Journal:  J Neuroinflammation       Date:  2012-12-19       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.